Podoplanin: A potential therapeutic target for thrombotic diseases

Area of Science:

• Biomedical research
• Molecular biology
• Pathology

Background:

• Podoplanin (Pdpn) is a lymphatic marker and CLEC-2 ligand involved in physiological and pathological processes.
• Thrombotic diseases, including atherosclerosis, stroke, and myocardial infarction, are leading causes of mortality.
• Thrombosis and inflammation are key factors in the pathogenesis of thrombotic diseases.

Purpose of the Study:

• To review current research on the roles and mechanisms of podoplanin in thrombotic diseases.
• To discuss the potential of podoplanin-targeted therapies for disease management.

Main Methods:

• Literature review of studies investigating podoplanin in various thrombotic conditions.
• Analysis of evidence regarding PDPN expression and function in disease states.
• Discussion of challenges and opportunities for podoplanin-targeted approaches.

Main Results:

• Podoplanin is increasingly recognized for its distribution and function in thrombotic diseases like atherosclerosis, ischemic stroke, and myocardial infarction.
• Evidence suggests PDPN can be acquired by cells under ischemic conditions, even if not normally expressed.
• The review synthesizes findings on PDPN's involvement in thrombosis and inflammation.

Conclusions:

• Podoplanin plays a significant role in the development and progression of thrombotic diseases.
• Targeting podoplanin presents potential avenues for disease prognosis and prevention, though challenges remain.
• Further research is needed to fully elucidate PDPN mechanisms and therapeutic potential.